Advertisement
Research Article

Aberrant DNA Methylation of OLIG1, a Novel Prognostic Factor in Non-Small Cell Lung Cancer

  • Romulo M Brena,

    Affiliations: Department of Molecular Genetics, The Ohio State University, Columbus, Ohio, United States of America, Department of Molecular Virology, Immunology and Medical Genetics, Division of Human Cancer Genetics, The Ohio State University, Columbus, Ohio, United States of America

    X
  • Carl Morrison,

    Affiliation: Department of Pathology, The Ohio State University, Columbus, Ohio, United States of America

    X
  • Sandya Liyanarachchi,

    Affiliation: Department of Molecular Virology, Immunology and Medical Genetics, Division of Human Cancer Genetics, The Ohio State University, Columbus, Ohio, United States of America

    X
  • David Jarjoura,

    Affiliation: Division of Biostatistics, College of Medicine and Public Health, The Ohio State University, Columbus, Ohio, United States of America

    X
  • Ramana V Davuluri,

    Affiliation: Department of Molecular Virology, Immunology and Medical Genetics, Division of Human Cancer Genetics, The Ohio State University, Columbus, Ohio, United States of America

    X
  • Gregory A Otterson,

    Affiliation: Department of Internal Medicine, Division of Hematology and Oncology, College of Medicine and Public Health, The Ohio State University, Columbus, Ohio, United States of America

    X
  • David Reisman,

    Affiliation: Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, Michigan, United States of America

    X
  • Selina Glaros,

    Affiliation: Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, Michigan, United States of America

    X
  • Laura J Rush,

    Affiliation: Department of Veterinary Biosciences and the Comprehensive Cancer Center, The Ohio State University Columbus, Ohio, United States of America

    X
  • Christoph Plass mail

    To whom correspondence should be addressed. E-mail: christoph.plass@osumc.edu

    Affiliation: Department of Molecular Virology, Immunology and Medical Genetics, Division of Human Cancer Genetics, The Ohio State University, Columbus, Ohio, United States of America

    X
  • Published: March 27, 2007
  • DOI: 10.1371/journal.pmed.0040108

About the Authors

Romulo M Brena
Department of Molecular Genetics, The Ohio State University, Columbus, Ohio, United States of America
Carl Morrison
Department of Pathology, The Ohio State University, Columbus, Ohio, United States of America
Romulo M Brena, Sandya Liyanarachchi, Ramana V Davuluri, Christoph Plass
Department of Molecular Virology, Immunology and Medical Genetics, Division of Human Cancer Genetics, The Ohio State University, Columbus, Ohio, United States of America
David Jarjoura
Division of Biostatistics, College of Medicine and Public Health, The Ohio State University, Columbus, Ohio, United States of America
Gregory A Otterson
Department of Internal Medicine, Division of Hematology and Oncology, College of Medicine and Public Health, The Ohio State University, Columbus, Ohio, United States of America
David Reisman, Selina Glaros
Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, Michigan, United States of America
Laura J Rush
Department of Veterinary Biosciences and the Comprehensive Cancer Center, The Ohio State University Columbus, Ohio, United States of America

Corresponding Author

Email: christoph.plass@osumc.edu

Competing Interests

The authors have declared that no competing interests exist.

Author Contributions

RMB, SL, and CP designed the study. RMB, CM, SL, DJ, RVD, and CP analyzed the data. RMB and CM collected data or did experiments for the study. DJ critiqued drafts and performed reanalysis and analysis of new data to address concerns. GAO reviewed the primary data and the clinical data and provided clinical context regarding lung cancer to the OLIG methylation status. DR built two lung cancer tissue microarrays and collected the clinical follow-up data for ∼200 lung cancer cases. LJR contributed to data interpretation. RMB, CM, SL, DJ, RVD, GAO, DR, SG, LJR, and CP contributed to writing the paper.